Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, McCoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA.
Aredo JV, et al. Among authors: wakelee ha.
J Thorac Oncol. 2021 Jun;16(6):1030-1041. doi: 10.1016/j.jtho.2021.01.1628. Epub 2021 Feb 12.
J Thorac Oncol. 2021.
PMID: 33588109
Free article.